Literature DB >> 33566441

Re-emergence of influenza virus circulation during 2020 in parts of tropical Asia: Implications for other countries.

Joshua A Mott1, Alicia M Fry2, Rebecca Kondor2, David E Wentworth2, Sonja J Olsen2.   

Abstract

Entities:  

Keywords:  H3N2 subtype; Influenza A virus; Southeastern Asia; sentinel surveillance; tropical climate

Year:  2021        PMID: 33566441      PMCID: PMC8051733          DOI: 10.1111/irv.12844

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


× No keyword cloud information.
Global influenza virus circulation declined and has been below traditional seasonal levels during the COVID‐19 pandemic. , , After learning of increased influenza virus circulation in some tropical Asian countries, we reviewed current surveillance data to better ascertain risk for an influenza resurgence during the 2020‐2021 Northern Hemisphere influenza season and subsequent seasons during the COVID‐19 pandemic. We reviewed WHO influenza surveillance outputs from May 1 to December 31, 2020 (epidemiologic weeks 18‐53) from tropical Asian countries that have land mass between the Tropics of Cancer and Capricorn. We excluded China and Australia, which have influenza seasons that generally follow temperate seasonal patterns. We identified countries that tested surveillance specimens for influenza viruses ≥50% of the 36 weeks (19/36 weeks). For each country, we report influenza surveillance specimens tested, and the percentage positive for influenza, by type and subtype; we compared current data to historical data from 2015 to 2019. Of 17 countries, 12 (70%) reported testing influenza surveillance specimens for more than half of the weeks during May 1 to December 31, 2020 (Table 1). These 12 countries tested 17,407 surveillance specimens, with 592 (3.4%) positive for influenza viruses. Influenza A(H3N2) viruses were detected in 573/592 (97%) influenza positive specimens. From April 27 to July 26, 2020 (epidemiologic weeks 18‐30), specimens tested decreased from an average of 14,102 per year in 2015‐2019 to 3,969 (71.9% decrease) and influenza positivity from 22% to ≤ 1%. During weeks 31‐53, specimens tested decreased from an average of 24,782 per year in 2015‐2019 to 13,438 (45.8% decrease) and influenza positivity from 18% to 4%.
TABLE 1

Laboratory‐confirmed influenza reported to WHO/FluNet among tropical Asian countries that maintained influenza surveillance during 2020: Epidemiologic weeks 18‐53, 2015‐2020

Country

Influenza virus circulation,

2020

Influenza virus circulation,

2015‐2019

Most recent week of reportMost recent week of influenza detection

Number of weeks with specimens processed

(% of 36 weeks)

Specimens tested during epidemiologic weeks 18‐53Influenza detected during weeks 18‐53 a Epidemiologic weeks during weeks 18‐53, with influenza virus detectionsInfluenza surveillance specimens tested and number positive in weeks 18‐30Influenza surveillance specimens tested and number positive in weeks 31‐53Influenza surveillance specimens tested and number positive in weeks 18‐30Influenza surveillance specimens tested and number positive in weeks 31‐53
Bangladesh524535 (97%)3,552208 A(H3)25, 32‐45

1/745

(0.1%)

207/2,807

(12%)

3,420/10,591 (32%)1,151/13,954 (8%)
Cambodia524635 (97%)737108 A(H3)27,29, 31‐46

3/285

(1%)

105/452

(23%)

463/1,663

(28%)

819/2,957

(28%)

India515130 (83%)2,17613 A(H3)41‐45, 47, 50‐51

0/574

(0%)

13/1,602

(1%)

1,825/12,889

(14%)

5,013/33,936

(15%)

Indonesia413622 (61%)131

3 A(H3)

20, 34, 36

1/66

(2%)

2/65

(3%)

769/3,784

(20%)

1,205/5,958 (20%)
Lao PDR525134 (94%)2,205

116 A(H3)

1 A(H1)

32, 36, 38‐51

0/390

(0%)

117/1,815

(6%)

447/6,459

(7%)

2,103/10,405

(20%)

Malaysia503431 (86%)1,6071 A(H1)34

0/563

(0%)

1/1,044

(0.1%)

653/5,790

(11%)

1,042/8,239 (13%)
Maldives53n/a20 (56%)1380n/a

0/47

(0%)

0/91

(0%)

419/1,334

(31%)

191/1,332

(14%)

New Caledonia53n/a36 (100%)4620n/a

0/236

(0%)

0/226

(0%)

489/2,098

(23%)

514/2,495

(21%)

Singapore53n/a36 (100%)1,4970n/a

0/398

(0%)

0/1,099

(0%)

1,951/4,217 (46%)1,536/4,645 (33%)
Thailand434326 (72%)741

3 A(H1)

1 B

36,37,43

0/252

(0%)

4/489

(1%)

1,033/3,939 (26%)2,628/8,231 (32%)
Timor‐Leste474621 (58%)2,772

14 A(H3)

12 A(H1)

1 B

30, 32‐33, 38‐42, 44, 46

8/49

(16%)

19/2,723

(1%)

99/293

(34%)

4/347

(1%)

Viet Nam505033 (92%)1,389

111 A(H3

40‐50

0/364

(0%)

111/1,025

(11%)

848/3,349

(25%)

1,276/6,627 (19%)
Total17,407

573 A(H3)

17 A(H1)

2 B

13/3,969 (0.3%)

579/13,438

(4%)

12,516/56,406 (22%)17,482/99,126 (18%)

Brunei (not in WHO FluNet), Myanmar (11 weeks), Papua New Guinea (0 weeks), Philippines (0 weeks), and Sri Lanka (3 weeks) did not report over 50% of weeks with influenza specimens processed to meet inclusion criteria (data last accessed on January 15, 2021).

The years 2015 and 2020 included 53 epidemic weeks. The years 2016‐2019 included 52 epidemic weeks.

Laboratory‐confirmed influenza reported to WHO/FluNet among tropical Asian countries that maintained influenza surveillance during 2020: Epidemiologic weeks 18‐53, 2015‐2020 Influenza virus circulation, 2020 Influenza virus circulation, 2015‐2019 Number of weeks with specimens processed (% of 36 weeks) 1/745 (0.1%) 207/2,807 (12%) 3/285 (1%) 105/452 (23%) 463/1,663 (28%) 819/2,957 (28%) 0/574 (0%) 13/1,602 (1%) 1,825/12,889 (14%) 5,013/33,936 (15%) 3 A(H3) 1/66 (2%) 2/65 (3%) 769/3,784 (20%) 116 A(H3) 1 A(H1) 0/390 (0%) 117/1,815 (6%) 447/6,459 (7%) 2,103/10,405 (20%) 0/563 (0%) 1/1,044 (0.1%) 653/5,790 (11%) 0/47 (0%) 0/91 (0%) 419/1,334 (31%) 191/1,332 (14%) 0/236 (0%) 0/226 (0%) 489/2,098 (23%) 514/2,495 (21%) 0/398 (0%) 0/1,099 (0%) 3 A(H1) 1 B 0/252 (0%) 4/489 (1%) 14 A(H3) 12 A(H1) 1 B 8/49 (16%) 19/2,723 (1%) 99/293 (34%) 4/347 (1%) 111 A(H3 0/364 (0%) 111/1,025 (11%) 848/3,349 (25%) 573 A(H3) 17 A(H1) 2 B 579/13,438 (4%) Brunei (not in WHO FluNet), Myanmar (11 weeks), Papua New Guinea (0 weeks), Philippines (0 weeks), and Sri Lanka (3 weeks) did not report over 50% of weeks with influenza specimens processed to meet inclusion criteria (data last accessed on January 15, 2021). The years 2015 and 2020 included 53 epidemic weeks. The years 2016‐2019 included 52 epidemic weeks. Six countries (Bangladesh, Kingdom of Cambodia, Lao PDR, New Caledonia, Singapore, and Viet Nam) maintained testing of surveillance specimens for >90% of weeks. In these countries, we observed considerable variability in influenza circulation. Influenza circulation was unseasonably low, or absent, during weeks 18‐30, 2020. However, during weeks 31‐53, the percentage of surveillance specimens testing positive for influenza approached or reached positivity rates of 2015‐2019 in Bangladesh and Cambodia and increased but remained lower than historical positivity in Lao PDR and Viet Nam. No influenza viruses were reported by New Caledonia and Singapore. Many countries in tropical Asia are struggling to conduct influenza surveillance in 2020, likely due to disruptions from the COVID‐19 pandemic. However, unlike the observation in the Southern Hemisphere , , influenza has not disappeared from circulation, and some countries experienced a delayed resurgence of community circulation of influenza viruses. The heterogeneity in the magnitude of the influenza activity across countries in tropical Asia is noteworthy and likely due to multiple factors, including surveillance artifact, degree of travel restrictions, and adherence to COVID‐19 interventions. This has important implications for the 2020‐2021 Northern Hemisphere influenza season, and for future influenza vaccine strain selection. First, it is critical that persons recommended to receive influenza vaccinations get vaccinated. The COVID‐19 pandemic is disproportionately impacting older persons, those with underlying chronic conditions, and other traditionally underserved populations, , many of whom are also at increased risk of severe complications of influenza. Influenza vaccination could prevent unnecessary morbidity and mortality and ease the strain on healthcare facilities. Second, maintaining surveillance and outbreak response is essential to track the geographic spread and obtain viruses so vaccines remain optimized to circulating influenza viruses. At the WHO Collaborating Center for Reference and Research on Influenza at CDC Atlanta, global surveillance submitted 583 influenza viruses to CDC between March 1 and September 30, 2020, a 69% decrease from an average of 1908 viruses during the same months in the years 2015‐2019. Furthermore, the limited data from tropical Asia suggest that genetically divergent influenza A(H3N2) viruses are currently in circulation. Some viruses from Cambodia and Bangladesh belong to a different genetic clade, 3C.2a1b + T131K, than the currently recommended 2020‐2021 Northern Hemisphere influenza vaccine virus, A/Hong Kong/267/2019, which comes from genetic clade 3C.2a1b + 135K+137F. The data presented here are a reminder that the low levels of influenza circulation seen in the Northern Hemisphere in summer 2020 may not necessarily persist into the upcoming influenza season, and influenza surveillance and prevention strategies should continue as planned and not be delayed.

CONFLICT OF INTEREST

The findings and conclusions in this report are those of the authors and do not necessarily represent the official of the Centers for Disease Control and Prevention.

AUTHOR CONTRIBUTION

Joshua Mott: Conceptualization (equal); Data curation (lead); Formal analysis (lead); Validation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Alicia M. Fry: Conceptualization (equal); Funding acquisition (equal); Supervision (lead); Writing‐review & editing (equal). Rebecca JG Kondor: Data curation (supporting); Formal analysis (supporting); Validation (equal); Writing‐original draft (supporting); Writing‐review & editing (equal). David Wentworth: Data curation (equal); Formal analysis (supporting); Supervision (equal); Writing‐original draft (supporting); Writing‐review & editing (supporting). Sonja J. Olsen: Conceptualization (equal); Data curation (equal); Formal analysis (equal); Methodology (equal); Supervision (equal); Validation (equal); Writing‐original draft (equal); Writing‐review & editing (equal).
  7 in total

1.  Addressing Influenza Vaccination Disparities During the COVID-19 Pandemic.

Authors:  Lisa A Grohskopf; Leandris C Liburd; Robert R Redfield
Journal:  JAMA       Date:  2020-09-15       Impact factor: 56.272

2.  Decreased Influenza Activity During the COVID-19 Pandemic - United States, Australia, Chile, and South Africa, 2020.

Authors:  Sonja J Olsen; Eduardo Azziz-Baumgartner; Alicia P Budd; Lynnette Brammer; Sheena Sullivan; Rodrigo Fasce Pineda; Cheryl Cohen; Alicia M Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-09-18       Impact factor: 17.586

3.  Re-emergence of influenza virus circulation during 2020 in parts of tropical Asia: Implications for other countries.

Authors:  Joshua A Mott; Alicia M Fry; Rebecca Kondor; David E Wentworth; Sonja J Olsen
Journal:  Influenza Other Respir Viruses       Date:  2021-02-10       Impact factor: 4.380

4.  Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand.

Authors:  Q Sue Huang; Tim Wood; Lauren Jelley; Tineke Jennings; Sarah Jefferies; Karen Daniells; Annette Nesdale; Tony Dowell; Nikki Turner; Priscilla Campbell-Stokes; Michelle Balm; Hazel C Dobinson; Cameron C Grant; Shelley James; Nayyereh Aminisani; Jacqui Ralston; Wendy Gunn; Judy Bocacao; Jessica Danielewicz; Tessa Moncrieff; Andrea McNeill; Liza Lopez; Ben Waite; Tomasz Kiedrzynski; Hannah Schrader; Rebekah Gray; Kayla Cook; Danielle Currin; Chaune Engelbrecht; Whitney Tapurau; Leigh Emmerton; Maxine Martin; Michael G Baker; Susan Taylor; Adrian Trenholme; Conroy Wong; Shirley Lawrence; Colin McArthur; Alicia Stanley; Sally Roberts; Fahimeh Rahnama; Jenny Bennett; Chris Mansell; Meik Dilcher; Anja Werno; Jennifer Grant; Antje van der Linden; Ben Youngblood; Paul G Thomas; Richard J Webby
Journal:  Nat Commun       Date:  2021-02-12       Impact factor: 14.919

5.  Decreased Influenza Incidence under COVID-19 Control Measures, Singapore.

Authors:  Roy Jiunn Jye Soo; Calvin J Chiew; Stefan Ma; Rachael Pung; Vernon Lee
Journal:  Emerg Infect Dis       Date:  2020-04-27       Impact factor: 6.883

6.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

Authors:  Zhaohai Zheng; Fang Peng; Buyun Xu; Jingjing Zhao; Huahua Liu; Jiahao Peng; Qingsong Li; Chongfu Jiang; Yan Zhou; Shuqing Liu; Chunji Ye; Peng Zhang; Yangbo Xing; Hangyuan Guo; Weiliang Tang
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

7.  Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020.

Authors:  Sheena G Sullivan; Sandra Carlson; Allen C Cheng; Monique Bn Chilver; Dominic E Dwyer; Melissa Irwin; Jen Kok; Kristine Macartney; Jennifer MacLachlan; Cara Minney-Smith; David Smith; Nigel Stocks; Janette Taylor; Ian G Barr
Journal:  Euro Surveill       Date:  2020-11
  7 in total
  11 in total

1.  Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children.

Authors:  Jianru Qin; Jilei Lin; Xiangfei Zhang; Shuhua Yuan; Chiyu Zhang; Yong Yin
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

2.  Re-emergence of influenza virus circulation during 2020 in parts of tropical Asia: Implications for other countries.

Authors:  Joshua A Mott; Alicia M Fry; Rebecca Kondor; David E Wentworth; Sonja J Olsen
Journal:  Influenza Other Respir Viruses       Date:  2021-02-10       Impact factor: 4.380

3.  Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021.

Authors:  Sonja J Olsen; Amber K Winn; Alicia P Budd; Mila M Prill; John Steel; Claire M Midgley; Krista Kniss; Erin Burns; Thomas Rowe; Angela Foust; Gabriela Jasso; Angiezel Merced-Morales; C Todd Davis; Yunho Jang; Joyce Jones; Peter Daly; Larisa Gubareva; John Barnes; Rebecca Kondor; Wendy Sessions; Catherine Smith; David E Wentworth; Shikha Garg; Fiona P Havers; Alicia M Fry; Aron J Hall; Lynnette Brammer; Benjamin J Silk
Journal:  Am J Transplant       Date:  2021-10       Impact factor: 9.369

4.  Different Circulation Pattern of Multiple Respiratory Viruses in Southern China During the COVID-19 Pandemic.

Authors:  Zhiqi Zeng; Wenda Guan; Yong Liu; Zhengshi Lin; Wenhua Liang; Jingyi Liang; Bingqian Chen; Tong Wu; Yutao Wang; Chunguang Yang; Qiubao Wu; Zhitong Mai; Jinchao Zhou; Junhou Zhou; Zhoulang Wang; Zhijie Lin; Chaohui Hu; Chunqiu Wu; Pengyuan Zhu; Canxiong Chen; Nanshan Zhong; Eric H Y Lau; Chitin Hon; Yaoming Liang; Zifeng Yang; Jianxing He
Journal:  Front Microbiol       Date:  2022-01-26       Impact factor: 5.640

5.  The role of non-pharmaceutical interventions on influenza circulation during the COVID-19 pandemic in nine tropical Asian countries.

Authors:  William W Davis; Joshua A Mott; Sonja J Olsen
Journal:  Influenza Other Respir Viruses       Date:  2022-01-08       Impact factor: 4.380

6.  Dynamics of influenza-like illness under urbanization procedure and COVID-19 pandemic in the subcenter of Beijing during 2013-2021.

Authors:  Chao Wang; Yan-Na Yang; Lu Xi; Li-Li Yang; Juan Du; Zhong-Song Zhang; Xin-Yao Lian; Yan Cui; Hong-Jun Li; Wan-Xue Zhang; Bei Liu; Fuqiang Cui; Qing-Bin Lu
Journal:  J Med Virol       Date:  2022-04-28       Impact factor: 20.693

Review 7.  Influenza.

Authors:  Timothy M Uyeki; David S Hui; Maria Zambon; David E Wentworth; Arnold S Monto
Journal:  Lancet       Date:  2022-08-27       Impact factor: 202.731

Review 8.  Subtype H3N2 Influenza A Viruses: An Unmet Challenge in the Western Pacific.

Authors:  Min Kang; Mark Zanin; Sook-San Wong
Journal:  Vaccines (Basel)       Date:  2022-01-12

9.  Genetic and Antigenic Characterization of an Influenza A(H3N2) Outbreak in Cambodia and the Greater Mekong Subregion during the COVID-19 Pandemic, 2020.

Authors:  Ian G Barr; Erik A Karlsson; Jurre Y Siegers; Vijaykrishna Dhanasekaran; Ruopeng Xie; Yi-Mo Deng; Sarika Patel; Vanra Ieng; Jean Moselen; Heidi Peck; Ammar Aziz; Borann Sarr; Savuth Chin; Seng Heng; Asheena Khalakdina; Michael Kinzer; Darapheak Chau; Philomena Raftery; Veasna Duong; Ly Sovann
Journal:  J Virol       Date:  2021-09-29       Impact factor: 5.103

10.  Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021.

Authors:  Sonja J Olsen; Amber K Winn; Alicia P Budd; Mila M Prill; John Steel; Claire M Midgley; Krista Kniss; Erin Burns; Thomas Rowe; Angela Foust; Gabriela Jasso; Angiezel Merced-Morales; C Todd Davis; Yunho Jang; Joyce Jones; Peter Daly; Larisa Gubareva; John Barnes; Rebecca Kondor; Wendy Sessions; Catherine Smith; David E Wentworth; Shikha Garg; Fiona P Havers; Alicia M Fry; Aron J Hall; Lynnette Brammer; Benjamin J Silk
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-07-23       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.